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Because micronutrients from plants may have beneficial cardiovascular effects, the hypothesis
that an encapsulated juice powder concentrate might affect several measures of vascular health
was tested in free living adults at low cardiovascular risk. Blood pressure, vascular compliance,
lipid and antioxidant markers, and serial electron beam tomography (to calculate a coronary
artery calcium score as a measure of atherosclerosis burden), were monitored in 51 pre-
hypertensive and hypertensive subjects over 2 years. By the end of follow-up, systolic
and diastolic blood pressure decreased significantly ( 2.4 1.0mmHg, P50.05 and
 2.2 0.6mmHg, P50.001), and large artery compliance improved significantly
(1.9 0.6mlmmHg
 1 100, P50.01). The progression of coronary artery calcium score was
smaller than expected compared with a historical database (P50.001). Laboratory testing
showed a significant decrease in homocysteine (P¼0.05), HDL cholesterol (P¼0.025) and Apo
A( P¼0.004), as well as a significant increase in b-carotene, folate, Co-Q10 and a-tocopherol
(all P50.001). The phytonutrient concentrate we utilized induced several favorable modifica-
tions of markers of vascular health in the subjects. This study supports the notion that plant
nutrients are important components of a heart healthy diet.
Keywords: antioxidant – blood pressure – coronary artery calcium – fruit – hypertension –
vegetable
Introduction
The protective effects of fruits and vegetables against
coronary heart disease and myocardial infarction have
been reported in numerous populations worldwide (1–5).
In observational studies, antioxidant vitamins, associated
with an increased dietary intake of fruits and vegetables,
have been inversely associated with cardiovascular disease
and all-cause mortality (6–8). Despite theoretical
advantages, supportive laboratory and epidemiological
evidence, randomized clinical trials of selected antiox-
idant vitamins (A, C, E) and selenium have produced
conflicting results related to coronary heart disease and
cardiovascular disease (9–15). Of interest, some cultures
rely heavily on the effect of herbal medicines for control
of hyperlipidemia, hypertension and other ailments (16).
Currently, both the American Heart Association
Science Advisory Council and the American College of
Cardiology do not recommend the use of single
antioxidant vitamin supplements for cardiovascular pre-
vention; nonetheless, these organizations do recommend
the consumption of a diet high in sources of antioxidants
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properly cited.and other nutrients such as fruits, vegetables, whole
grains and nuts to reduce the risk of cardiovascular
disease (17,18).
This prospective pilot study was undertaken to evaluate
the effect of a proprietary encapsulated juice powder
concentrate, made primarily of multiple fruits, vegetables
and berries on several surrogate markers of cardio-
vascular health and risk in asymptomatic adults. Assessed
were: progression of coronary artery calcium score,
a sensitive marker of atherosclerosis; systemic and
diastolic blood pressure; arterial compliance; markers
of antioxidant status and serum lipid levels in patients
taking the phytonutrient preparation for 2 years.
Methods
Subjects
This 24-month prospective pilot study was approved by
the local Institutional Review Board. Informed consent
was obtained from 54 ambulatory patients (44 men)
between the ages of 40 and 75 years asymptomatic for
coronary heart disease. Subjects were recruited from the
Hypertension Institute and the Saint Thomas Medical
Group practices in Nashville, TN, USA. All subjects were
asymptomatic for coronary heart disease (no clinical
history of angina, myocardial infarction, coronary
revascularization) and had a coronary artery calcium
score at enrollment between 30 and 400. The lower
coronary artery calcium score threshold was chosen
based on published evidence demonstrating better repro-
ducibility beyond this limit (19). A coronary artery
calcium score 4400 has been shown to be associated
with a high risk of obstructive coronary artery disease
and cardiac events and it was therefore decided a priori to
exclude such high risk patients. Further inclusion criteria
included baseline fasting LDL cholesterol54.92mmoll
 1
and triglycerides 54.52mmoll
 1, and two or fewer risk
factors for coronary heart disease. Exclusion criteria
included symptomatic angina or known coronary heart
disease, single vessel coronary artery stenosis over 50%
or left main artery stenosis over 30%. Additional
exclusion criteria were use of any lipid lowering
therapy, concomitant use of any antioxidant, vitamin,
nutritional or nutraceutical supplements and women of
childbearing potential.
After enrollment, no changes were allowed in anti-
hypertensive medications, other prescription drugs or
aspirin during the study period. No dietary or activity
instructions were given, rather participants were
asked to maintain their habitual diet, exercise program,
tobacco utilization, alcohol intake and other lifestyle
behaviors. Subjects underwent follow-up visits at
4-month intervals.
Imaging, Vascular Compliance, Blood Pressure
Measurements and Laboratory Testing
All patients underwent imaging with electron beam
tomography 3 times: at baseline, 12 and 24 months
(though these time points were not tightly monitored and
some patients underwent the repeat scans at slightly
different times but no more than a week or two from the
planned time). All electron beam tomography scans were
performed utilizing a C-150 scanner (Imatron/GE,
San Francisco, CA, USA) according to a standardized
protocol. In brief: 40 to 50 tomographic sections with
a single slice thickness of 3mm were obtained during a
single breath holding period. Scanning was electrocardio-
graphically triggered at 60–80% of the R–R interval on
the surface electrocardiogram and imaging began at the
level of the bronchial carina and extended to the level of
the diaphragm. All areas of calcification with a minimal
computed tomography attenuation of 130 Hounsfield
Units seen within the borders of the coronary arteries
were computed. A calcified plaque was considered
present if at least three contiguous pixels with a density
of 130 Hounsfield Units or greater were detected.
All images were reviewed on a NetraMD workstation
(ScImage, Los Altos,CA, USA).
Scans were considered of acceptable research quality
only if the images were free from motion or metal
artifacts. All scans were read blindly by one (BJO)
experienced investigator for consistency. A coronary
artery calcium score for each area of interest was
calculated as originally described by Agatston et al. (20).
This scoring method incorporates the density and volume
of a calcified plaque, therefore a score increase may be due
to either plaque enlargement or increased density or both.
T h er e v e r s ew o u l db et r u ef o ras c o r ed e c r e a s e .T o t a l
calcium scores were calculated as the sum of all individual
coronary artery scores. The published median inter-scan
coronary artery calcium score variability for the Agatston
score is 8–10% (21). The total radiation dose absorbed by
each patient from the three scans was of  1.5mSievert
(the maximum recommended yearly dose is 5 mSv for
nonmedical personnel in the US).
The CV Profiler-HDI CR-2000 (Hypertension
Diagnostics Incorporated, Eagan, Minnesota) was
utilized for assessment of arterial wave forms and small
vessel as well as large vessel arterial compliance.
Compliance is measured as the change in vessel diameter
and volume per each mmHg of pressure change
(ml/mmHg
 1 100). Arterial compliance was measured
at baseline, 12 and 24 months.
Baseline history, physical exam, blood pressure, weight,
and heart rate measurements were repeated every
4 months for 24 months. Blood pressure was recorded
as the average of two manual measurements and
three automated measurements, taken after the subject
lay in a supine position for 15min. Laboratory tests for
456 Phytonutrient effects on vascular markersb-carotene, a-tocopherol, folate, Co-Q10, vitamin C,
glycated hemoglobin and a lipid profile were performed
by a commercial diagnostic laboratory (Kronos Science
Laboratories, Inc., Phoenix, AZ, USA). Blood samples
were collected at baseline, 4 months and 24 months.
Nutritional Intervention
Subjects were instructed to take three capsules of the
phytonutrient preparation twice daily with meals.
Compliance with study protocol was determined by
review of patient diaries and investigators’ pill count at
each visit, and averaged 85% or better during the follow-
up period. The phytonutrient preparation (Juice Plusþ,
NSA, Inc., Memphis,TN, USA) is an encapsulated juice
powder concentrate blend consisting primarily of fruits,
vegetables and berries including: acerola cherry, apple,
beet, bilberry, blackberry, black currant, blueberry,
broccoli, cabbage, carrot, cranberry, Concord grape,
elderberry, kale, orange, papaya, parsley, peach, pine-
apple, raspberry, red currant, spinach and tomato.
Six capsules daily provided  7.5mg b-carotene, 276mg
vitamin C, 71mg vitamin E and 780mcg folate
and about 63kJ. Other than minor gastrointestinal
complaints early in the study, there were no reports of
adverse effects attributed to the phytonutrient prepara-
tion over the 24 months of follow-up.
Statistical Analyses
Of the 54 subjects entering the investigation, three with-
drew before the first follow-up visit. One woman withdrew
due to the prescription of a medication excluded from the
study and two men due to gastrointestinal distress possibly
due to the phytonutrient preparation. The remaining
51 subjects contributed data. One man withdrew consent
after the 4-month follow-up visit, one man withdrew
consent after the 8-month follow-up visit, three subjects
(one woman, two men) withdrew consent after the
12-month follow-up visit and one man withdrew from
the study due to prescription of an excluded medication.
These six subjects are included in the data until the time
of their withdrawal. Hence, comparisons were made only
between patients who had baseline assessments and
remained in the study at each analysis point.
Annualized change and relative annualized change were
calculated for each patient at 1- and 2-year intervals for
blood pressure values, weight, arterial compliance values,
coronary artery calcium score values (absolute scores
and percentiles) and blood chemistries. Coronary artery
calcium score percentiles were calculated as the proportion
of patients with coronary calcium in predefined and
non-overriding age groups from a database of 10122
asymptomatic patients (22). The annualized rates of
absolute change and relative change in coronary artery
calcium score were compared to changes recorded in
historical untreated controls of 29.7 and 34.7%, respec-
tively, (23) using one-sample t-tests. In general, changes
were annualized for primarily two reasons: patients did not
return for follow-up visits at precise 12-month intervals,
and annualization facilitates the comparison between
changes at intervals of 12 and 24 months (Table 1).
Annualization was also important when analyzing
coronary artery calcium score values because comparative
historical data were only available in annualized format.
In each case, the paired t-statistic was used to construct
confidence intervals and to test for significant annualized
changes between baseline and follow-up among all
patients first and pre-hypertensive and hypertensive
patients later. The one-sample Wilcoxon test on medians
was used to confirm significance in this case. Welch’s
t-test was used to compare all baseline values of pre-
hypertensive and hypertensive patients, and significant
results were confirmed using the Mann–Whitney rank
sum test. Best-subsets regression was used to study how
age, sex, hypertension, and baseline body weight, arterial
compliance values and coronary calcium measures were
related to the annualized changes over 2 years in systemic
blood pressure, arterial compliance and coronary calcium
Table 1. Annualized changes at 12- and 24-month follow-up for coronary artery calcium scores, arterial compliance, and blood pressure, with values




a 26 6.3*** (18, 204)*** 17 3.2*** (14, 108)***
Relative calcium score 26 6.2*** (22, 213)*** 20 4.0*** (20, 167)***
Calcium score percentile 1.3 1.1 (2.8, 42)* 1.1 0.6 (1.7, 22)*
Small artery compliance (mlmmHg
 1 100) 0.34 0.43 (0.00, 17.1)  0.14 0.21 ( 0.30, 6.5)
Large artery compliance (mlmmHg
 1 100) 1.5 1.3 (0.4, 47) 1.9 0.6** (1.5, 17)**
Systolic blood pressure (mmHg)  3.0 2.0 ( 1.4, 74)  2.4 1.0* ( 1.5, 27)*
Diastolic blood pressure (mmHg)  3.0 1.0** ( 2.8, 27)**  2.2 0.61*** ( 2.0, 16)**
*P50.05; **P50.01; ***P50.001 (relative to baseline) by paired t-test (and Wilcoxon one-sample test).
aCalcium score comparisons with historical 29.7-point annual change: these are significant relative to annualized 24-month change for full cohort
(P50.001), 24-month change for pre-hypertensives (P50.01) and 24-month change for hypertensives (P50.05); it is not significantly different from
the 12-month change in the full cohort.
eCAM 2007;4(4) 457measurements. The best models were chosen as those that
minimized the Bayesian Information Criterion (BIC)
subject to the constraint that the ratio of observations
to parameters exceeded 5, but this ratio actually exceeded
10 for all selected models. The BIC has been shown
to be a consistent criterion in very general theoretical
settings and to provide models that perform well in
empirical studies.
Results
Baseline Characteristics and Change in Coronary Artery
Calcium Score
The baseline clinical characteristics of all patients
enrolled in the study are shown in Table 2. Most of the
study subjects were hypertensive (n¼38), although
some were classified as pre-hypertensive (n¼13).
The majority were men (80%) and the mean age was
61 6.5 years. Table 1 shows the mean annualized
changes (measured change divided by number of months
of observation andmultiplied by12) at12 and24 months of
follow-up for coronary artery calcium scores, arterial
compliance and blood pressure. The annualized change
in absolute coronary artery calcium score was 26 6 points
at 12 months (P50.001 from baseline) and 17 3.2 points
at 24 months (P50.001 from baseline). These values
corresponded to a relative change of 26 6 and 20 4%,
respectively from baseline (P50.001 in each case).
In comparison, the annualized change in absolute and
relative coronary artery calcium score in historical
untreated controls were 29.7 and 34.7%, respectively (23)
(P50.001 for each, one-sample t-tests).
Change in Arterial Blood Pressure and Compliance
Figure 1 shows the change over time in systolic blood
pressure and Fig. 2 shows the change over time in
Table 2. Baseline clinical characteristics
Clinical characteristics Full cohort Pre-hypertensive subjects Hypertensive subjects
Sample size 51 13 38
Men (%) 80 69 84
Hyperlipidemia (%) 55 69 50
Diabetes mellitus (%) 4 0 5
Smoking (%) 6 0 8
Hypertension (%) 75 – 100
Mean SD (median, range) Mean SD (median, range) Mean SD (median, range)
Age (years) 61 6.5 (61, 28) 59 6.6 (58, 26) 62 6.4 (62, 26)
Systolic blood pressure (mmHg) 134 18 (129, 74) 120 14 (115, 44) 139 17*** (135, 60)***
Diastolic blood pressure (mmHg) 82 9.3 (82, 40) 76 7.5 (74, 25) 85 9.0** (84, 35)**
Weight (kg) 91 15 (88, 73) 86 14.5 (88, 50) 92 16 (90, 60)
Small artery compliance (mlmmHg
 1 100) 5.3 2.7 (4.5, 10) 6.6 2.4 (6.6, 7.2) 4.8 2.7* (4.1, 10)*
Large artery compliance (mlmmHg
 1 100) 15.0 5.2 (14.7, 23.7) 14.9 6.2 (13.6, 22.7) 15.0 4.8 (14.9, 23.5)
Calcium score 99 73 (76, 322) 109 74 (93, 255) 95.3 73 (75, 321)
Calcium score percentile 47 19 (50, 74) 58 16 (61, 55) 44 19* (44, 67)*
Total cholesterol (mmoll
 1) 5.33 0.79 (5.33, 3.36) 5.64 0.86 (5.87, 2.64) 5.22 0.74 (5.18, 3.36)
HDL cholesterol (mmoll
 1) 1.20 0.39 (1.11, 1.84) 1.21 0.37 (1.11, 1.45) 1.19 0.40 (1.06, 1.84)
LDL cholesterol (mmoll
 1) 3.45 0.64 (3.57, 2.97) 3.61 0.75 (3.83, 2.59) 3.40 0.60 (3.54, 2.66)
Triglycerides (mmoll
 1) 1.42 0.68 (1.23, 3.04) 1.67 0.71 (1.40, 2.28) 1.34 0.66 (1.18, 3.04)
Apo A (gl
 1) 1.41 0.30 (1.32, 1.68) 1.42 0.25 (1.44, 0.97) 1.41 0.32 (1.32, 1.68)
Apo B (gl
 1) 1.10 0.17 (1.09, 0.70) 1.14 0.20 (1.13, 0.66) 1.08 0.15 (1.07, 0.69)
Glycosylated hemoglobin, proportion of total hemoglobin 0.055 0.008 (0.056, 0.050) 0.052 0.006 (0.055, 0.019) 0.057 0.008 (0.057, 0.050)
Homocysteine (mmoll
 1) 10.4 2.3 (10.2, 10.7) 10.5 2.5 (9.8, 8.3) 10.3 2.2 (10.2, 10.0)
Vitamin C (mmoll
 1) 675 195 (650, 761) 776 216 (715, 647) 640 177 (619, 727)
Co-Q10 (nmoll
 1) 1451 530 (1415,3642) 1415 317 (1508, 940) 1463 588 (1404, 3515)
Folate (nmoll
 1)2 5  8 (24, 35) 26 9 (24, 30) 25 8 (25,35)
a-tocopherol (mmoll
 1) 315 72 (308, 325) 346 86 (351, 301) 304 65 (303, 261)
b-carotene (mmoll
 1) 4.2 3.7 (2.9, 15.4) 6.4 5.2 (4.0, 14.9) 3.4 2.7 (2.8, 11.2)
Values expressed as percentages, mean SD, and median and range where appropriate.
The P-values refer to comparisons between pre-hypertensive and hypertensive patients: *P50.05; **P50.01; ***P50.001 by Welch’s t-test
(and Mann–Whitney rank sum test).
458 Phytonutrient effects on vascular markersdiastolic blood pressure from baseline, at each of the six
follow-up visits. Both measures decreased significantly
in the full cohort at the end of 2 years of follow-up
compared with baseline (systolic  2.4 1.0mmHg,
P50.05 and diastolic  2.2 0.6mmHg, P50.001) in
the absence of any modification in anti-hypertensive
therapy. Large artery compliance improved significantly
(1.9 0.6mlmmHg
 1 100, P50.01), while small artery
compliance showed a slight but non-significant decrease.
Changes in Serological Values
Table 3 shows that compared with baseline, at the end
of 24 months of follow-up there was a significant
decrease in homocysteine (P50.05), HDL cholesterol
(P¼0.025) and Apo A (P¼0.004). Additionally, a
significant increase was seen in b-carotene, folate,
Co-Q10 and a-tocopherol (all P50.001). Finally, glyco-
sylated hemoglobin showed a borderline significant
decrease (P¼0.059), and LDL cholesterol a borderline
significant increase (P¼0.062).
Regression Analyses
Table 4 summarizes the best models for all significant
2-year changes (Table 1) in systemic blood pressure,
arterial compliance and coronary calcium measurements.
The baseline values of these variables, along with age,
sex, and baseline weight, were considered as candidate
predictors. Hypertension is significant in models for both
change and relative change in calcium score, and baseline
systolic blood pressure is the pre-eminent predictor in
both models for change in systemic blood pressure.
Discussion
Our main findings could be summarized as follows: the
mean calcium score changes at the end of follow-up in
this group were statistically smaller than the changes
recorded in an historical population (29.7 and 34.7%,
respectively, P50.001 in each case). In addition, these
pilot study subjects also had reduced systemic blood
pressure in the presence of stable anti-hypertensive
therapy and improved vascular compliance of large
arteries in the absence of change in body weight (data
not shown). The above changes were concurrent with an
improvement in markers of antioxidant status, homo-
cysteine and glycosylated hemoglobin.
These data may provide a rationale for the observed
reduced incidence of coronary heart disease in vegetar-
ians, who demonstrate a 3–5 year overall longer survival
compared to omnivores. The European Prospective
Investigation into Cancer and Nutrition-Oxford study
of 56000 British men and women demonstrated a
reduced risk for coronary heart disease in vegetarians
(24). In several observational studies components of a
plant-based diet, such as phytochemicals (25), fiber (26),
nuts (27) and whole grain cereals (28), have been
shown to reduce the risk for coronary heart disease.
Furthermore, vegetarian diets, coupled with intense life
style changes, have resulted in angiographic improvement
of obstructive coronary artery disease (29). Multiple
studies have suggested that an optimal intake of fruits,
vegetables, whole grains and fiber may provide a
variety of cardio-protective nutrients and non-nutrient
factors with improvement in endothelial function, blood
pressure, serum lipid levels, glucose, homocysteine,
weight, body fat and reduction in oxidative stress and
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Diastolic blood pressure
Figure 2. Diastolic blood pressure change over time, shown by full
cohort and the hypertensive and pre-hypertensive subgroups, with each
box plot showing the distribution of subject values for recorded
diastolic blood pressure measured at baseline and 4-month intervals for
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Full cohort Pre-hypertensive Hypertensive
Systolic blood pressure
Figure 1. Systolic blood pressure change over time, shown by full
cohort and the hypertensive and pre-hypertensive subgroups, with each
box plot showing the distribution of subject values for recorded systolic
blood pressure measured at baseline and 4-month intervals for six
follow-up visits. The means of each distribution are connected across
periods.
eCAM 2007;4(4) 459that a plausible explanation for such favorable effects
may be a nutrient–gene interaction that contributes to
a reduction in coronary heart disease.
Coronary artery calcification is an excellent marker
of atherosclerosis and its presence is associated with
a substantially increased risk of cardiac events (35–38).
Some investigators have suggested modifying the calcu-
lated Framingham Risk Score with data derived from
calcium screening, thereby increasing or decreasing the
estimated risk of an event (39,40). Calcium screening
could be particularly helpful in patients at intermediate
risk of events (36) where the presence of calcium increases
(and its absence decreases) the probability of an event.
In this light, a middle-aged man with hypertension
(as most of the patients in our study) may benefit from
calcium screening for more accurate risk stratification.
Recently, sequential coronary artery calcium scoring has
been used to monitor the progression of atherosclerosis in
adults treated with lipid-lowering agents (38), phosphate
binding agents in renal failure (41) as well as nutritional
Table 4. Best models for variables of Table 1 that changed significantly over 24 months in terms of baseline values (for all Table 1 variables, along
with sex, weight, and hypertension)
Dependent (R-square) 24-month annualized change in: Predictor from baseline Coefficient (SE) P-value Univariate P-value
Calcium score (34%)
Constant  11.9 (6.65) 0.082
Hypertension 16.7 (5.78) 0.006 0.080
Calcium score 0.187 (0.0424) 0.000 0.001
Calcium relative change (9%)
No constant
a
Hypertension 0.253 (0.0456) 0.000 0.028
Large artery compliance (8%)
Constant 5.378 (1.77) 0.004
Large artery C  0.242 (0.118) 0.046 0.046
Systolic blood pressure (53%)
Constant 24.2 (5.35) 0.000
Female  7.51 (2.15) 0.001 0.005
Systolic  0.192 (0.0399) 0.000 50.001
Diastolic blood pressure (51%)
Constant 9.34 (4.50) 0.047
Weight 0.0284 (0.0133) 0.042 0.059
Systolic  0.131 (0.0246) 0.000 50.001
aWhen a constant is added to this model its coefficient is larger than its standard error. In each case, the direction of univariate association is the
same as the sign of multivariate coefficient.
Table 3. Baseline and annualized 24-month change in lipids and other blood values expressed as mean SD
Variable Baseline Annualized 24-month change P-value (Wilcoxon P)
Total cholesterol (mmoll
 1) 5.33 0.79 (5.33, 3.36) 0.04 0.32 (0.08, 1.5) 0.368 (0.132)
HDL cholesterol (mmoll
 1) 1.20 0.39 (1.11, 1.84)  0.03 0.09 ( 0.03, 0.43) 0.025 (0.027)
LDL cholesterol (mmoll
 1) 3.45 0.64 (3.57, 2.97) 0.09 0.32 (0.10, 1.3) 0.062 (0.027)
Triglycerides (mmoll
 1) 1.42 0.68 (1.23, 3.04)  0.03 0.32 ( 0.01, 1.5) 0.492 (0.438)
Apo A (gl
 1) 1.41 0.30 (1.32, 1.68)  0.05 0.11 ( 0.04, 0.54) 0.004 (0.002)
Apo B (gl
 1) 1.10 0.17 (1.09, 0.70)  0.02 0.08 ( 0.03, 0.31) 0.171 (0.093)
Glycosylated hemoglobin, proportion of total hemoglobin 0.055 0.008 (0.056, 0.050)  0.001 0.005 ( 0.002, 0.032) 0.059 (0.043)
Homocysteine (mmoll
 1) 10.4 2.3 (10.2, 10.7)  0.26 0.77 ( 0.10, 3.18) 0.050 (0.110)
Vitamin C (mmoll
 1) 675 195 (650, 761) 35 140 (8.2, 810) 0.097 (0.214)
Co-Q10 (nmoll
 1) 1451 530 (1415,3642) 477 358 (414, 1996) 50.001 (50.001)
Folate (nmoll
 1)2 5  8 (24, 35) 3.2 3.4 (3.5, 19) 50.001 (50.001)
Alpha-tocopherol (mmoll
 1) 315 72 (308, 325) 52 43 (46, 237) 50.001 (50.001)
Beta-carotene (mmoll
 1) 4.2 3.7 (2.9, 15.4) 1.4 2.0 (1.2, 11) 50.001 (50.001)
460 Phytonutrient effects on vascular markerssupplements (42). Of note, progression of coronary
artery calcium score has been shown to be associated
with a significant increase in risk of cardiovascular events
(23,38). Hence, slowing of coronary artery calcium
score progression appears to be a worthy goal of therapy.
Importantly, the best predictor of coronary artery
calcium score progression in this study was hypertension,
suggesting the very significant role played by this risk
factor in progression of atherosclerosis.
Abnormal arterial compliance, an accurate marker of
vascular stiffness, has been shown to be associated with
aging, multiple cardiovascular risk factors and with an
adverse cardiovascular outcome (43). Improvement in
arterial compliance in this pilot study is further evidence
of the potentially favorable effects of fruits and
vegetables on the overall vascular health of an individual.
While the importance of antioxidants in the reduction
of cardiovascular disease remains controversial, the
parallel reduction of oxidative stress and other markers
of vascular damage are reassuring. In this light, it is
intriguing that a powder concentrate containing numer-
ous phytonutrients, as opposed to tablets of single
vitamins, was sufficient to attain the favorable surrogate
results demonstrated.
We have no biologically plausible explanation for Juice
Plusþ alone (in the absence of a change in weight as
discussed earlier) to have any impact on cholesterol
lipoprotein concentrations. Juice Plusþ has been shown
to impact LDL cholesterol oxidation, but not total
amount of LDL cholesterol and no effect on HDL has
ever been demonstrated. Even though a diet high in
fruits, vegetables and whole grains is beneficial regarding
lipoprotein concentrations, this effect is largely attributed
to the fiber components of these foods. When cholesterol
was monitored more closely, as in the study by Plotnick
et al. (44), no consistent effect was noted. In observa-
tional studies a reduction, and not an increase, in LDL
cholesterol has been associated with lack of progression
of coronary artery calcium (45), while there has been no
study so far of the effect of HDL level modification on
coronary calcium. Hence, one would have expected a
negative effect on calcium progression from the observed
changes in cholesterol lipoprotein but this did not occur.
To further investigate this issue, we searched the human
medical literature for evidence that b-carotene or vitamin
E may impact lipid concentrations, but found no
evidence for such an effect.
Limitations of this pilot study included the small
sample size and lack of a placebo group. The comparison
of change in coronary artery calcium score compared
to the historical database is not optimal because of
temporal differences of when that data were collected,
along with other potential differences between this
study population and the contributors to the database
information. In addition, although some investigators
have raised concerns about the reliability of the CR-2000
used to assess arterial compliance (42), others have
disputed this opinion and finding the CR-2000 highly
reproducible (46).
In summary, this pilot study showed a favorable effect
of an encapsulated juice powder concentrate, made
primarily of multiple fruits, vegetables and berries, on
several surrogate markers of cardiovascular disease.
Additional placebo-controlled prospective studies will be
required to confirm these findings.
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